Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 26


Probing Amyloid-β Pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI Imaging Mass Spectrometry.

Carlred L, Michno W, Kaya I, Sjövall P, Syvänen S, Hanrieder J.

J Neurochem. 2016 Apr 26. doi: 10.1111/jnc.13645. [Epub ahead of print]


Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease.

Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvänen S.

Nat Commun. 2016 Feb 19;7:10759. doi: 10.1038/ncomms10759.


(R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model.

Bogdanović RM, Syvänen S, Michler C, Russmann V, Eriksson J, Windhorst AD, Lammertsma AA, de Lange EC, Voskuyl RA, Potschka H.

Neuropharmacology. 2014 Oct;85:104-12. doi: 10.1016/j.neuropharm.2014.05.002. Epub 2014 May 28.


[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness.

Syvänen S, Russmann V, Verbeek J, Eriksson J, Labots M, Zellinger C, Seeger N, Schuit R, Rongen M, van Kooij R, Windhorst AD, Lammertsma AA, de Lange EC, Voskuyl RA, Koepp M, Potschka H.

Nucl Med Biol. 2013 Aug;40(6):764-75. doi: 10.1016/j.nucmedbio.2013.05.008. Epub 2013 Jul 1.


Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain.

Magnusson K, Sehlin D, Syvänen S, Svedberg MM, Philipson O, Söderberg L, Tegerstedt K, Holmquist M, Gellerfors P, Tolmachev V, Antoni G, Lannfelt L, Hall H, Nilsson LN.

J Alzheimers Dis. 2013;37(1):29-40. doi: 10.3233/JAD-130029.


Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Syvänen S, Eriksson J.

ACS Chem Neurosci. 2013 Feb 20;4(2):225-37. doi: 10.1021/cn3001729. Epub 2012 Dec 4. Review.


Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET.

Syvänen S, Labots M, Tagawa Y, Eriksson J, Windhorst AD, Lammertsma AA, de Lange EC, Voskuyl RA.

J Nucl Med. 2012 Dec;53(12):1974-83. doi: 10.2967/jnumed.112.104588. Epub 2012 Nov 9.


Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.

Müllauer J, Kuntner C, Bauer M, Bankstahl JP, Müller M, Voskuyl RA, Langer O, Syvänen S.

EJNMMI Res. 2012 Oct 16;2(1):58. doi: 10.1186/2191-219X-2-58.


[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats.

Verbeek J, Eriksson J, Syvänen S, Labots M, de Lange EC, Voskuyl RA, Mooijer MP, Rongen M, Lammertsma AA, Windhorst AD.

EJNMMI Res. 2012 Jul 2;2(1):36. doi: 10.1186/2191-219X-2-36.


[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein.

Froklage FE, Syvänen S, Hendrikse NH, Huisman MC, Molthoff CF, Tagawa Y, Reijneveld JC, Heimans JJ, Lammertsma AA, Eriksson J, de Lange EC, Voskuyl RA.

EJNMMI Res. 2012 Mar 28;2:12. doi: 10.1186/2191-219X-2-12.


Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil.

Verbeek J, Syvänen S, Schuit RC, Eriksson J, de Lange EC, Windhorst AD, Luurtsema G, Lammertsma AA.

Nucl Med Biol. 2012 May;39(4):530-9. doi: 10.1016/j.nucmedbio.2011.10.017. Epub 2012 Jan 5.


Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate.

Syvänen S, Schenke M, van den Berg DJ, Voskuyl RA, de Lange EC.

AAPS J. 2012 Mar;14(1):87-96. doi: 10.1208/s12248-011-9318-1. Epub 2012 Jan 4.


Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: comparison of full saturation and steady state methods.

Syvänen S, de Lange EC, Tagawa Y, Schenke M, Molthoff CF, Windhorst AD, Lammertsma AA, Voskuyl RA.

Neuroimage. 2011 Aug 1;57(3):928-37. doi: 10.1016/j.neuroimage.2011.05.022. Epub 2011 May 14.


(R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.

Syvänen S, Luurtsema G, Molthoff CF, Windhorst AD, Huisman MC, Lammertsma AA, Voskuyl RA, de Lange EC.

BMC Med Imaging. 2011 Jan 3;11:1. doi: 10.1186/1471-2342-11-1.


Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs.

Syvänen S, Hammarlund-Udenaes M.

Curr Top Med Chem. 2010;10(17):1799-809. Review.


Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.

Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, Hammarlund-Udenaes M.

Drug Metab Dispos. 2009 Mar;37(3):635-43. doi: 10.1124/dmd.108.024745. Epub 2008 Dec 1.


A computerized infusion pump for control of tissue tracer concentration during positron emission tomography in vivo pharmacokinetic/pharmacodynamic measurements.

Eriksson O, Wallberg A, Syvänen S, Josephsson R, Långström B, Bergström M.

BMC Med Phys. 2008 May 30;8:2. doi: 10.1186/1756-6649-8-2.


Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier.

Syvänen S, Hooker A, Rahman O, Wilking H, Blomquist G, Långström B, Bergström M, Hammarlund-Udenaes M.

J Pharm Sci. 2008 Dec;97(12):5386-400. doi: 10.1002/jps.21359.


On the rate and extent of drug delivery to the brain.

Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A.

Pharm Res. 2008 Aug;25(8):1737-50. Epub 2007 Dec 5. Review.


Synthesis of two potential NK1-receptor ligands using [1-11C]ethyl iodide and [1-11C]propyl iodide and initial PET-imaging.

Syvänen S, Eriksson J, Genchel T, Lindhe O, Antoni G, Långström B.

BMC Med Imaging. 2007 Jul 30;7:6.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk